Related Experiment Video

Updated: May 24, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Cardiorenal disease development under chronic renin-angiotensin-aldosterone system suppression

Pantelis A Sarafidis1, Luis M Ruilope

  • 1Academic Department of Renal Medicine, King's College Hospital, London, UK.

Journal of the Renin-Angiotensin-Aldosterone System : JRAAS
|March 6, 2012
PubMed

Insights

Drugs that suppress the renin-angiotensin-aldosterone system (RAAS) are common for cardiorenal conditions. Further research is needed to understand and treat cardiorenal disease progression despite RAAS suppression.

Area of Science:

  • Cardiology
  • Nephrology
  • Pharmacology

Background:

  • Renin-angiotensin-aldosterone system (RAAS) suppressors are widely used for cardiorenal diseases.
  • Arterial hypertension patients often receive long-term treatment with ACE inhibitors and ARBs.

Purpose of the Study:

  • To clarify the significance of cardiorenal disease progression during RAAS suppression.
  • To identify strategies to reduce the rate of cardiorenal disease progression under RAAS suppression.

Main Methods:

  • Observational studies analyzing patient data.
  • Analysis of disease progression markers in patients on RAAS inhibitors.
  • Comparative studies of different RAAS-suppressing drug classes.

Main Results:

  • Cardiorenal disease progression is observed in patients despite RAAS suppression.
  • The exact mechanisms driving this progression require further investigation.
  • Current RAAS-suppressing therapies may not fully halt cardiorenal disease advancement.

Conclusions:

  • Understanding cardiorenal disease progression under RAAS suppression is crucial.
  • New therapeutic targets or strategies are needed to improve outcomes.
  • Optimizing RAAS-targeted therapies may be necessary to slow disease progression.

More Related Videos

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.